[Webinar] How to better optimize an oncology drug discovery program
Register for this webinar discussing how conventional and innovative integrated technological skills should be incorporated into an oncology program.Read more
SOLO COVID-19 is the product of Oncodesign’s pharmacological expertise combined with our agility and societal commitment. This offer was swiftly deployed in 2020, allowing – with rigor and safety – the implementation of specific in vitro and in vivo pharmacology studies to evaluate new prophylactic, therapeutic or vaccinal approaches to combat COVID-19.
In collaboration with our partners IDMIT and SEPIA of the CEA, SOLO Covid-19 offers the ability to evaluate the efficacy of new therapeutic options as well as repositioning of pre-existing options.
This offer is based on the use of an integrated panel of biochemical and cellular assays, including animal models, infected with SARS-CoV-2 or modeling inflammatory pulmonary complications.
INPACT: an integrated service in preclinical pharmacology